Alterity Therapeutics
ATHE · NASDAQ · Health Care · Pharmaceutical Preparations
Pharmaceutical Preparations company based in Melbourne, Australia. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
As of Oct 20, 2026, OQRO holds for Alterity Therapeutics (ATHE) over the last 12 months: 5 insider filings, 0 Congress trades, 0 fund positions and 0 federal contract awards. Most recent on file: Director purchased ~$24K of ATHE shares in the open market, traded Aug 31, 2026, filed Sep 9, 2026.
On the public record for Alterity Therapeutics over the 12 months to Oct 20, 2026: 1 clinical trial.
Example public filing
Director bought ~$24K
Peter Ashley Marks, Director at Alterity Therapeutics, bought ~$24K of Alterity Therapeutics shares.
- ~$24K
- Approx. value · 48K sh @ $0.50
- 191K
- Holds after · shares reported
- Traded
- Aug 31, 2026
- Filed
- Sep 9, 2026
Data as of Oct 20, 2026. A real record from the official source, chosen as the most recent insider trade or, failing that, the most recent filing of another kind; not a recommendation.
On file for ATHE, last 12 months
- 5
- Insider filings
- 0
- Congress trades
- 0
- Fund positions
- 0
- Federal contracts
Records OQRO holds, counted by their date; a 13F position is counted once per quarter it is reported.
Insider buying and selling since 2026
Insiders of Alterity Therapeutics reported 1 open-market purchase and 0 sales since 2026; purchases in 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | 1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. The amounts, the people and every filing are in OQRO Pro.
See the full picture with OQRO Pro.
5 records for Alterity Therapeutics in the last 12 months, each linked to its filing. Full histories, the screener, alerts for the companies you follow and Ask OQRO.
Latest disclosures
3 days free for first-time subscribers, then $9.99 a month. Nothing is charged today: your card is charged when the trial ends unless you cancel before, from your account. Secure payment by Stripe.
Public previews are free. Full research is OQRO Pro, with a 3-day free trial to start: your card is charged only when the trial ends.
Free account: get the written context of this page, built from its filings.
What this page holds
- Insider trades and planned sales
- Politician trades (House and Senate)
- Fund holdings from 13F filings
- Federal contracts, lobbying and short selling
- Full history and context, with a link to every filing
What OQRO is
OQRO reads the public record for US-listed companies — insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings, and federal contract awards — and puts each one in plain words next to the filing it came from. It describes what was disclosed. It does not give investment advice or tell you what to buy.
Want to see real filings before you pay? The home page shows live ones, free, with the link to each source document.
Questions about Alterity Therapeutics insider trading
Have Alterity Therapeutics insiders bought shares recently?
Yes. Insiders of Alterity Therapeutics (ATHE) filed 1 open-market purchase in the last 90 days; the latest was filed on Sep 9, 2026.
How often do Alterity Therapeutics insiders buy and sell shares?
Since 2026, Alterity Therapeutics insiders reported 1 open-market purchase and 0 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2026.
Do members of Congress trade ATHE?
No trade in Alterity Therapeutics (ATHE) was disclosed by a member of Congress in the last 12 months.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.